Strengthening antimicrobial resistance governance in Europe: a coordinated one health approach
Antimicrobial resistance (AMR) causes over 35,000 deaths annually in the EU/EEA and is projected to result in 1.91 million global deaths each year by 2050. The second Joint Action on Antimicrobial Resistance and Healthcare-Associated Infections (EU-JAMRAI-2), uniting 128 partners from 30 countries, represents a coordinated EU/EEA effort to curb AMR through a One Health approach. Although nearly all EU/EEA countries have an AMR National Action Plan, our initial assessment revealed that implementation remains constrained by limited resources, weak intersectoral coordination and fragmented leadership. EU-JAMRAI-2 addresses these challenges by promoting harmonized surveillance, strengthening infection prevention and control, applying behaviorally tailored stewardship interventions, ensuring sustainable access to essential antibiotics, and raising awareness among priority target audiences. By analyzing policy gaps and operational barriers, this paper underscores the need for stronger accountability and political commitment to translate strategies into sustainable action. Strengthening AMR governance through a unified European approach is essential to achieve effective, lasting progress against this silent pandemic.
Institutions
- Université Claude Bernard Lyon 1 (FR)
- Statens Serum Institut (DK)
- Public Health Agency of Sweden (SE)
- Ministry of Health Welfare and Sport (NL)
- Norwegian Institute of Public Health (NO)
- Inserm (FR)
- Université de Versailles Saint-Quentin-en-Yvelines (FR)
- Université Paris-Saclay (FR)
- Servei de Salut de les Illes Balears (ES)
- Departament de Salut (ES)
- Assistance Publique – Hôpitaux de Paris (FR)
- Institut Català d'Oncologia (ES)
- Ministère des Solidarités et de la Santé (FR)
- Centre Hospitalier Universitaire de Limoges (FR)
- Hôpital Raymond-Poincaré (FR)
- Agence Nationale de Sécurité Sanitaire de l’Alimentation, de l’Environnement et du Travail (FR)
- Bioef - Fundación Vasca de Innovación e Investigación Sanitarias (ES)
- National Public Health Organization (GR)
- Institut Català de la Salut (ES)
- Université de Limoges (FR)
- Pharmaceuticals and Medical Devices Agency (JP)
Publication Details
- Journal
- The Lancet Regional Health - Europe
- Published
- 2025-11-19
- DOI
- https://doi.org/10.1016/j.lanepe.2025.101540
- Citations
- 2
- Primary Topic
- Antibiotic Use and Resistance
- Type
- article
- Field-Weighted Citation Impact
- 2.52